Lp(a)

Beyond LDL-C: Understanding Cardiovascular Risk With PREVENT, ApoB, Lp(a), Non-HDL-C and Advanced Lipid Analysis

by David Mcauley - August 7, 2026August 11, 2026 0507

GlobalRPh Clinical TechnologyBeyond LDL-C: Understanding Cardiovascular Risk With PREVENT, ApoB, Lp(a), Non-HDL-C and Advanced Lipid AnalysisIntroducing the GlobalRPh Cardiovascular Risk and Advanced Lipid Analyzer, a layered cardiovascular prevention tool that combines the standard lipid panel with advanced lipoprotein markers, derived calculations, kidney and metabolic context, coronary calcium, and the American

The Rise of Precision Lipidology: Beyond LDL-C to ApoB, Lp(a), and Atherogenic Particle Burden

by Similoluwa Oluwalana - May 15, 2026 0152

The Rise of Precision Lipidology: Beyond LDL-C to ApoB, Lp(a), and Atherogenic Particle Burden Review Abstract Lipidology is undergoing a clinically important transition from traditional cholesterol-centered assessment toward a more precise evaluation of atherogenic lipoprotein burden. Low-density lipoprotein cholesterol (LDL-C) remains a validated therapeutic target

Cholesterol Guidelines 2025: Should Age 40 Be the New Threshold for Statin Therapy?

by Similoluwa Oluwalana - July 11, 2025July 17, 2025 01922

Cholesterol Guidelines 2025: Should Age 40 Be the New Threshold for Statin Therapy? Introduction Cardiovascular disease (CVD) remains the leading cause of death for most racial and ethnic groups, with cholesterol guidelines playing a crucial role in prevention strategies. Dyslipidemia stands